Findings

What do systematic reviews say?

12 questions · 13 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 46.2%GRADE not reported 3 · 23.1%Very low 2 · 15.4%Low 1 · 7.7%Moderate 1 · 7.7%High 0 · 0%

Oxandrolone vs placebo

Muscle strength · people with inclusion body myositis

2 findings from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported
Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oxandrolone vs placebo

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported

Oxandrolone vs placebo

Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oxandrolone vs placebo

Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oxandrolone vs placebo

Significant adverse events · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Improvement in final adult height (cm)

1 finding from 1 review

Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 270 participants
Moderate

Intervention not reported

Adverse events (N)

The intervention showed no clear difference in adverse events (N) (low certainty).

1 finding from 1 review

Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome 2019 · Cochrane Headline outcomes only
RR 1.81 [0.83, 3.96]
2 studies · 170 participants
Low

Intervention not reported

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Effects on speech (voice frequency)

1 finding from 1 review

Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Intervention not reported

Effects on cognition(WISC‐R questionnaire)

1 finding from 1 review

Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Very low

Intervention not reported

Effects on psychological status (several questionnaires)

1 finding from 1 review

Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 106 participants
Very low

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found